Literature DB >> 14575772

Rabies DNA vaccine in the horse: strategies to improve serological responses.

Laurent Fischer1, Jules Minke, Nathalie Dufay, Philippe Baudu, Jean Christophe Audonnet.   

Abstract

In order for DNA vaccines to become a practical alternative to conventional vaccines their ability to induce antibody responses in large mammals needs to be improved. We used DNA vaccination against rabies in the horse as a model to test the potential of two different strategies to enhance antibody responses in a large mammalian species. The administration of the DNA vaccine in the presence of aluminum phosphate improved both the onset and the intensity of serological responses but was not potent enough to achieve seroconversion in all vaccinated ponies. However, when the DNA vaccine was formulated with the cationic lipid DMRIE-DOPE instead of aluminum phosphate, a very strong impact on both onset and intensity of serological responses was observed. This latter strategy ensured excellent seroconversion in all vaccinated ponies after a primary course of two injections, demonstrating a clear improvement of the homogeneity of the induced responses. These data indicate that rabies DNA vaccination is feasible in horses and further suggests that properly formulated DNA vaccines can generate immune responses in large veterinary species at a level comparable to the responses achieved with conventional vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14575772     DOI: 10.1016/s0264-410x(03)00504-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  A DNA fusion vaccine induces bactericidal antibodies to a peptide epitope from the PorA porin of Neisseria meningitidis.

Authors:  Delin Zhu; Jeannette N Williams; Jason Rice; Freda K Stevenson; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

2.  Experimental Rhodococcus equi and equine infectious anemia virus DNA vaccination in adult and neonatal horses: effect of IL-12, dose, and route.

Authors:  R H Mealey; D M Stone; M T Hines; D C Alperin; M H Littke; S R Leib; S E Leach; S A Hines
Journal:  Vaccine       Date:  2007-08-15       Impact factor: 3.641

3.  Enhancement of immunogenicity and efficacy of a plasmid DNA rabies vaccine by nanoformulation with a fourth-generation amine-terminated poly(ether imine) dendrimer.

Authors:  Padinjaremattathil Thankappan Ullas; Shampur Narayan Madhusudana; Anita Desai; Bhadravathi Kenchappa Chandrasekhar Sagar; Govindasamy Jayamurugan; Yamajala Bhaskara Rama Durga Rajesh; Narayanaswami Jayaraman
Journal:  Int J Nanomedicine       Date:  2014-01-28

Review 4.  Lyssaviruses: current trends.

Authors:  Susan A Nadin-Davis; Christine Fehlner-Gardiner
Journal:  Adv Virus Res       Date:  2008       Impact factor: 9.937

5.  Transcriptomic basis for an antiserum against Micrurus corallinus (coral snake) venom.

Authors:  Luciana I Leão; Paulo L Ho; Inacio de L M Junqueira-de-Azevedo
Journal:  BMC Genomics       Date:  2009-03-16       Impact factor: 3.969

6.  Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine.

Authors:  Michal Margalith; Adrián Vilalta
Journal:  Genet Vaccines Ther       Date:  2006-02-15

7.  Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge.

Authors:  Manpreet Kaur; Anant Rai; Rakesh Bhatnagar
Journal:  Vaccine       Date:  2009-02-06       Impact factor: 3.641

Review 8.  Equids' Core Vaccines Guidelines in North America: Considerations and Prospective.

Authors:  Hélène Desanti-Consoli; Juliette Bouillon; Ronan J J Chapuis
Journal:  Vaccines (Basel)       Date:  2022-03-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.